Krka d. d (KN8) Stock Overview
A generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for KN8 from our risk checks.
KN8 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Krka, d. d. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €255.00 |
| 52 Week High | €262.50 |
| 52 Week Low | €179.50 |
| Beta | 0.42 |
| 1 Month Change | 3.24% |
| 3 Month Change | 8.05% |
| 1 Year Change | 36.36% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 59.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| KN8 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.4% | 3.0% | 2.8% |
| 1Y | 36.4% | 23.4% | 1.4% |
Return vs Industry: KN8 exceeded the German Pharmaceuticals industry which returned 23.4% over the past year.
Return vs Market: KN8 exceeded the German Market which returned 1.4% over the past year.
Price Volatility
| KN8 volatility | |
|---|---|
| KN8 Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: KN8 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: KN8's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 11,667 | Jože Colaric | www.krka.biz |
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, and other therapeutic areas. It also provides non-prescription products for cough, cold, cerebral, peripheral circulation, gastrointestinal tract, metabolism, and other therapeutic areas, as well as analgesics, vitamins, minerals, and vasoprotectives.
Krka, d. d. Fundamentals Summary
| KN8 fundamental statistics | |
|---|---|
| Market cap | €7.76b |
| Earnings (TTM) | €372.00m |
| Revenue (TTM) | €2.08b |
Is KN8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KN8 income statement (TTM) | |
|---|---|
| Revenue | €2.08b |
| Cost of Revenue | €864.10m |
| Gross Profit | €1.22b |
| Other Expenses | €848.59m |
| Earnings | €372.00m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 23, 2026
| Earnings per share (EPS) | 12.27 |
| Gross Margin | 58.55% |
| Net Profit Margin | 17.84% |
| Debt/Equity Ratio | 0% |
How did KN8 perform over the long term?
See historical performance and comparisonDividends
Does KN8 pay a reliable dividends?
See KN8 dividend history and benchmarks| Krka d. d dividend dates | |
|---|---|
| Ex Dividend Date | Jul 21 2026 |
| Dividend Pay Date | Jul 23 2026 |
| Days until Ex dividend | 54 days |
| Days until Dividend pay date | 56 days |
Does KN8 pay a reliable dividends?
See KN8 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/27 18:53 |
| End of Day Share Price | 2026/05/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Krka, d. d. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Simon Mather | Barclays |
| Stephane Sumar | BNP Paribas |
| Jamie Clark | BofA Global Research |